KR102413828B1 - Method of Manufacturing and Taking Grub Powder - Google Patents
Method of Manufacturing and Taking Grub Powder Download PDFInfo
- Publication number
- KR102413828B1 KR102413828B1 KR1020190130690A KR20190130690A KR102413828B1 KR 102413828 B1 KR102413828 B1 KR 102413828B1 KR 1020190130690 A KR1020190130690 A KR 1020190130690A KR 20190130690 A KR20190130690 A KR 20190130690A KR 102413828 B1 KR102413828 B1 KR 102413828B1
- Authority
- KR
- South Korea
- Prior art keywords
- slugs
- drying
- drying step
- group
- slug powder
- Prior art date
Links
- 239000000843 powder Substances 0.000 title claims abstract description 48
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 20
- 238000001035 drying Methods 0.000 claims abstract description 54
- 241000237858 Gastropoda Species 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 25
- 238000001291 vacuum drying Methods 0.000 claims abstract description 7
- 238000000227 grinding Methods 0.000 claims abstract description 5
- 238000010298 pulverizing process Methods 0.000 claims abstract description 3
- 238000005406 washing Methods 0.000 claims abstract 2
- 230000006837 decompression Effects 0.000 claims description 12
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 28
- 235000013305 food Nutrition 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 10
- 230000036541 health Effects 0.000 description 9
- 235000018192 pine bark supplement Nutrition 0.000 description 9
- 229940106796 pycnogenol Drugs 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000023555 blood coagulation Effects 0.000 description 8
- 229950005499 carbon tetrachloride Drugs 0.000 description 8
- 229920002770 condensed tannin Polymers 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000013376 functional food Nutrition 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 6
- 206010067125 Liver injury Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 231100000234 hepatic damage Toxicity 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000008818 liver damage Effects 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003114 blood coagulation factor Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000007602 hot air drying Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000019750 Crude protein Nutrition 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 229940019700 blood coagulation factors Drugs 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 235000019784 crude fat Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000006623 intrinsic pathway Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000137592 Boettgerilla pallens Species 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 241000692770 Taraxia ovata Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229940124594 traditional oriental medicine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L35/00—Food or foodstuffs not provided for in groups A23L5/00 – A23L33/00; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/40—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
- A23L3/54—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution using irradiation or electrical treatment, e.g. ultrasonic waves
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/31—Mechanical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
개시되는 굼벵이 분말 제조방법은, 완숙된 굼벵이를 세척하고, 마이크로파(Micro Wave)를 이용한 저온 진공건조방식으로 세척된 상기 굼벵이의 함수율을 설정된 초기 함수율로 낮추는 1차 건조단계; 상기 1차 건조단계에서 제공되는 상기 굼벵이를 미리 설정된 건조온도 및 건조시간으로 건조하는 2차 건조단계; 및 상기 2차 건조단계에서 제공되는 상기 굼벵이를 분쇄하여 굼벵이 분말을 제조하는 분쇄단계;를 포함한다.The disclosed method for producing slug powder includes a primary drying step of washing mature slugs and lowering the moisture content of the slugs washed by a low temperature vacuum drying method using a microwave to a set initial moisture content; a secondary drying step of drying the slugs provided in the primary drying step at a preset drying temperature and drying time; and a grinding step of pulverizing the slugs provided in the secondary drying step to prepare slug powder.
Description
본 발명(Disclosure)은, 굼벵이 분말 제조방법 및 복용방법에 관한 것으로서, 구체적으로 간 손상 세포를 복구할 수 있는 굼벵이 분말 제조방법 및 복용방법에 관한 것이다.The present invention (Disclosure) relates to a method for preparing and taking a slug powder, and more particularly, to a method for preparing and taking a slug powder capable of repairing liver damaged cells.
여기서는, 본 발명에 관한 배경기술이 제공되며, 이들이 반드시 공지기술을 의미하는 것은 아니다(This section provides background information related to the present disclosure which is not necessarily prior art).Herein, background information related to the present invention is provided, which does not necessarily imply prior art (This section provides background information related to the present disclosure which is not necessarily prior art).
우리 농산물을 건강기능성식품의 원료로 적극 활용함으로써 외국산 건강기능식품의 수입에 능동적으로 대응하고, 국내 건강기능 식품산업을 육성하기 위해서 우리 농산물의 건강기능성, 안정성 등 우수성을 발굴할 필요가 있다.In order to actively respond to the import of foreign health functional food by actively using Korean agricultural products as raw materials for health functional food, and to foster the domestic health functional food industry, it is necessary to discover excellence in health functionality and stability of Korean agricultural products.
건강기능식품 생산은 국내외 경기침체에도 건강에 대한 관심이 높아지면서 새로운 기능성을 찾는 다양한 계층의 소비자욕구가 반영되어 성장세가 지속되는 것으로 분석되었음. It was analyzed that the growth of health functional food production continued, reflecting the consumer needs of various classes seeking new functionalities as interest in health increased despite the economic downturn at home and abroad.
2013년 건강기능식품 기능성원료 인정 현황을 분석한 결과, 개별인정형 건강기능식품 인정 전반적으로 줄어드는 추세 속에서 국내 제조 원료의 인정은 급증한 반면 수입 원료의 인정은 감소한 것으로 나타났다.As a result of analyzing the status of accreditation of functional ingredients for health functional food in 2013, it was found that while the accreditation of imported raw materials decreased while the accreditation of domestic manufacturing raw materials increased rapidly, while the overall accreditation of individually accredited health functional food was declining.
기능성별로는 면역기능 개선 관련제품의 점유율이 25%로 가장 높았고, 혈행개선 (22%), 항산화(21%), 영양소 보충(7%), 장 건강 (5%) 제품 순서이다.By function, products related to immune function improvement accounted for the highest share at 25%, followed by blood circulation improvement (22%), antioxidant (21%), nutrient supplementation (7%), and intestinal health (5%) products.
한편, 국내 곤충시장이 2011년 1680억 원에서 2015년 2980억 원으로 4년 만에 2배 가깝게 성장하는 등 혐오대상으로 여겨지던 곤충이 황금알을 낳는 신산업으로 관심이 집중되고 있다..Meanwhile, the domestic insect market has nearly doubled in four years from 168 billion won in 2011 to 298 billion won in 2015, attracting attention as a new industry in which insects, which were considered disgusting objects, lay golden eggs.
이에 곤충의 쓰임새가 식용, 농약 대체품, 식약 원료 등으로 빠르게 확장되는 추세이다.Accordingly, the use of insects is rapidly expanding to food, pesticide substitutes, and food and drug raw materials.
곤충 중에서도, 굼벵이는 민간 및 동의보감 등의 전통 한방의서에서 “제조”또는“굼벵이”라는 속명으로 불리어지고 있는 딱정벌레목, 풍뎅이과, 꽃무지아과에 속하며, 크기는 17 내지 24 센티미터의 초식성 곤충으로서, 우리나라를 비롯하여 중국, 일본 및 시베리아 동부지역에 서식하며, 5월에서 10월에 걸쳐 1내지 2년에 1회 발생한다고 알려 있다. Among insects, slugs belong to the orders Coleoptera, Scarabaceae, and Asteraceae, which are called “manufacturing” or “slugs” in traditional oriental medicine books such as folk and Donguibogam, and are herbivorous insects with a size of 17 to 24 centimeters, It inhabits Korea, China, Japan, and eastern Siberia, and is known to occur once every 1-2 years from May to October.
굼벵이는 오래전부터 간질환 등의 치료를 위한 한방 약재로서 이용되어 왔으며, 최근 유용한 생체 활성물질의 탐색 및 개발을 위한 곤충자원으로 크게 주목을 받고 있으며, 항생활성물질의 생산, 흰쥐(mouse)를 이용한 실험에서 알코올 과량섭취에 의해 손상된 간지질 대사의 회복작용 등이 알려져 있으며 혈전용해성 효소에 대한 연구와 집쥐(rat)에서 사염화탄소의 투여에 의해 유도된 간독성에 대한 간 보호효과를 나타내는 등 유용성이 확인된 바 있다.Slugs have long been used as oriental medicines for the treatment of liver diseases, etc., and have recently attracted great attention as an insect resource for the search and development of useful bioactive substances. In experiments, the effect of restoring liver lipid metabolism damaged by excessive alcohol intake is known, and its usefulness has been confirmed, such as a study on thrombolytic enzymes and a hepatoprotective effect on hepatotoxicity induced by the administration of carbon tetrachloride in rats. there is a bar
본 발명(Disclosure)은, 간 손상 세포를 복구할 수 있는 굼벵이 분말 제조방법 및 복용방법의 제공을 일 목적으로 한다.An object of the present invention (Disclosure) is to provide a method for preparing and taking a slug powder that can repair liver damaged cells.
여기서는, 본 발명의 전체적인 요약(Summary)이 제공되며, 이것이 본 발명의 외연을 제한하는 것으로 이해되어서는 아니 된다(This section provides a general summary of the disclosure and is not a comprehensive disclosure of its full scope or all of its features).Herein, a general summary of the present invention is provided, which should not be construed as limiting the scope of the present invention (This section provides a general summary of the disclosure and is not a comprehensive disclosure of its full scope or all of its features).
상기한 과제의 해결을 위해, 본 발명을 기술하는 여러 관점들 중 어느 일 관점(aspect)에 따른 굼벵이 분말 제조방법은, 완숙된 굼벵이를 세척하고, 마이크로파(Micro Wave)를 이용한 저온 진공건조방식으로 세척된 상기 굼벵이의 함수율을 설정된 초기 함수율로 낮추는 1차 건조단계; 상기 1차 건조단계에서 제공되는 상기 굼벵이를 미리 설정된 건조온도 및 건조시간으로 건조하는 2차 건조단계; 및 상기 2차 건조단계에서 제공되는 상기 굼벵이를 분쇄하여 굼벵이 분말을 제조하는 분쇄단계;를 포함한다.In order to solve the above problems, the slug powder manufacturing method according to any one aspect of the various aspects describing the present invention is to wash the mature slugs, and a low-temperature vacuum drying method using a microwave a primary drying step of lowering the water content of the washed slugs to a set initial moisture content; a secondary drying step of drying the slugs provided in the primary drying step at a preset drying temperature and drying time; and a grinding step of pulverizing the slugs provided in the secondary drying step to prepare slug powder.
본 발명의 다른 일 관점(aspect)에 따른 굼벵이 분말 제조방법에서, 상기 초기 함수율은 75% 내지 80%일 수 있다.In the method for producing slug powder according to another aspect of the present invention, the initial moisture content may be 75% to 80%.
본 발명의 다른 일 관점(aspect)에 따른 굼벵이 분말 제조방법에서, 상기 설정된 건조온도는 29℃ 내지 35℃이며, 상기 설정된 건조시간은 1시간 내지 2시간일 수 있다.In the slug powder manufacturing method according to another aspect of the present invention, the set drying temperature may be 29° C. to 35° C., and the set drying time may be 1 hour to 2 hours.
본 발명의 다른 일 관점(aspect)에 따른 굼벵이 분말 제조방법에서, 상기 1차 건조단계는, 세척된 상기 굼벵이를 진공챔버에 배치하고 감압하는 단계; 상기 진공챔버의 감압상태를 미리 정해진 감압 시간동안 유지하는 감압 유지단계; 상기 감압시간 경과후 상기 진공챔버 내부에 마이크로파를 인가하는 단계;를 포함하며, 상기 초기 함수율은 77%일 수 있다.In the method for producing slug powder according to another aspect of the present invention, the first drying step includes: placing the washed slugs in a vacuum chamber and reducing the pressure; a decompression maintaining step of maintaining the decompression state of the vacuum chamber for a predetermined decompression time; and applying a microwave to the inside of the vacuum chamber after the decompression time has elapsed, and the initial moisture content may be 77%.
상기한 과제의 해결을 위해, 본 발명을 기술하는 여러 관점들 중 어느 일 관점(aspect)에 따른 굼벵이 분말 복용방법은, 굼벵이 분말 제조방법으로 제조된 상기 굼벵이 분말을 복용자에게 경구 투여하는 단계를 포함하여, 상기 투여는 상기 복용자에게 하루에 100 내지 3,000mg/kg.B.W.의 상기 굼벵이 분말의 총 일일 투여량을 제공한다.In order to solve the above problem, the method for taking slug powder according to any one aspect of the various aspects describing the present invention includes the step of orally administering the slug powder prepared by the method for preparing the slug powder to the user. Thus, the dosing provides the recipient with a total daily dose of 100 to 3,000 mg/kg.B.W. of the slug powder per day.
본 발명의 다른 일 관점(aspect)에 따른 굼벵이 분말 복용방법에서, 상기 총 일일 투여량은 100 내지 300mg/kg.B.W.일 수 있다.In the method for taking slug powder according to another aspect of the present invention, the total daily dose may be 100 to 300 mg/kg.B.W.
본 발명의 다른 일 관점(aspect)에 따른 굼벵이 분말 복용방법에서, 상기 총 일일 투여량을 선택적으로 2회 또는 그 이상을 분할투여할 수 있다.In the slug powder dosage method according to another aspect of the present invention, the total daily dose may be selectively administered in two or more divided doses.
본 발명에 따르면, 굼벵이 분말을 복용함으로써, 간세포 손상을 복구 효과를 극대화 할 수 있다. According to the present invention, by taking slug powder, it is possible to maximize the effect of repairing liver cell damage.
도 1은 총 8군의 실험군의 혈액응고 저해활성.
도 2는 총 8군의 실험군의 간조직에 대한 조직학적 검사.1 is a blood coagulation inhibitory activity of a total of 8 groups.
2 is a histological examination of the liver tissue of the experimental group of a total of 8 groups.
이하, 본 발명에 따른 굼벵이 분말 제조방법 및 복용방법을 구현한 실시형태를 도면을 참조하여 자세히 설명한다.Hereinafter, an embodiment implementing the method for producing and taking the slug powder according to the present invention will be described in detail with reference to the drawings.
다만, 본 발명의 본질적인(intrinsic) 기술적 사상은 이하에서 설명되는 실시형태에 의해 그 실시 가능 형태가 제한된다고 할 수는 없고, 본 발명의 본질적인(intrinsic) 기술적 사상에 기초하여 통상의 기술자에 의해 이하에서 설명되는 실시형태를 치환 또는 변경의 방법으로 용이하게 제안될 수 있는 범위를 포섭함을 밝힌다. However, the intrinsic technical idea of the present invention cannot be said to be limited by the embodiments described below. It is revealed that the range that can be easily suggested as a method of substitution or modification of the embodiments described in is included.
또한, 이하에서 사용되는 용어는 설명의 편의를 위하여 선택한 것이므로, 본 발명의 본질적인(intrinsic) 기술적 사상을 파악하는 데 있어서, 사전적 의미에 제한되지 않고 본 발명의 기술적 사상에 부합되는 의미로 적절히 해석되어야 할 것이다. In addition, since the terms used below are selected for convenience of explanation, in grasping the intrinsic technical idea of the present invention, they are not limited to the dictionary meaning and are appropriately interpreted as meanings consistent with the technical spirit of the present invention. it should be
본 발명에 따른 굼벵이 분말 제조방법은, 1차 건조단계, 2차 건조단계, 및 분쇄단계를 포함한다. The method for producing slug powder according to the present invention includes a primary drying step, a secondary drying step, and a grinding step.
1차 건조단계는, 완숙된 굼벵이를 세척하고, 마이크로파를 이용한 저온 진공 건조방식을 이용하여, 세척된 굼벵이의 함수율을 설정된 초기 함수율로 낮춘다.In the first drying step, the mature slugs are washed, and the moisture content of the washed slugs is lowered to a set initial moisture content by using a low-temperature vacuum drying method using microwaves.
2차 건조단계는 1차 건조단계에서 제공되는 굼벵이를 미리 설정된 건조온도 및 건조시간으로 건조한다.In the second drying step, the slugs provided in the first drying step are dried at a preset drying temperature and drying time.
분쇄단계는 2차 건조단계에서 제공되는 굼벵이를 분쇄하여 굼벵이 분말을 제조한다.In the grinding step, the slugs provided in the secondary drying step are pulverized to prepare slug powder.
표 1은 종래의 굼벵이 분말 제조방법에 따라 제조된 굼벵이의 성분표이며, 표 2는 본 발명에 따른 굼벵이 분말 제조방법에 따라 제조된 굼벵이의 성분표이다.Table 1 is a table of ingredients of slugs prepared according to the conventional method for preparing slug powder, and Table 2 is a table of ingredients of slugs prepared according to the method for preparing slug powder according to the present invention.
표 1의 종래의 굼벵이 분말의 제조방법은, 일반적인 열풍 건조방법을 사용한다. The conventional method for producing slug powder in Table 1 uses a general hot air drying method.
일반적으로 사용되는 열풍 건조방법은, 45℃ ~ 50℃ 사이의 온도로 48시간 건조한다.A generally used hot air drying method is drying for 48 hours at a temperature between 45°C and 50°C.
표 1 및 표 2를 비교하면, 본 발명에 따른 굼벵이 분말 제조방법에 따라 제조된 굼벵이는, 종래의 굼벵이 분말 제조방법에 따라 제조된 굼벵이에 비교하여, 수분 및 단백질 함량이 더 높다. Comparing Tables 1 and 2, the slugs prepared according to the method for preparing slug powder according to the present invention have higher moisture and protein content, compared to slugs prepared according to the conventional method for preparing slug powder.
본 발명에 따른 굼벵이 분말 제조방법은, 마이크로파를 이용한 저온 진공 건조방법과 열풍 건조방법을 순차적으로 수행하는 2단계 건조 방법을 채용하였다.The method for producing slug powder according to the present invention employs a two-step drying method in which a low-temperature vacuum drying method using microwaves and a hot air drying method are sequentially performed.
마이크로파는, 건조 대상물 내부에 포함된 수분 자체에 전자기 에너지를 직접인가하므로, 영양소 파괴가 최소화 된다. 또한 건조 대상물을 진공상태에서 건조하면, 낮은 온도에서도 건조가 가능할 뿐만 아니라 건조 대상물의 표피에서 내부까지 균일한 건조상태를 형성할 수 있다.Since the microwave directly applies electromagnetic energy to the moisture itself contained in the drying object, the destruction of nutrients is minimized. In addition, if the object to be dried is dried in a vacuum state, it is possible to dry even at a low temperature and to form a uniform drying state from the epidermis to the inside of the object to be dried.
이에 따라 2차 건조단계에서도 낮은 온도에서 건조가 가능하며 굼벵이의 화학적 변성을 최대한 방지할 수 있다.Accordingly, it is possible to dry at a low temperature even in the secondary drying stage, and it is possible to prevent chemical transformation of slugs as much as possible.
본 발명에 따른 굼벵이 분말 제조방법에서, 초기 함수율은 75% 내지 80%이며, 77%가 바람직하다.In the method for producing slug powder according to the present invention, the initial moisture content is 75% to 80%, preferably 77%.
또한, 본 발명에 따른 굼벵이 분말 제조방법에서, 설정된 건조온도는 29℃ 내지 35℃이며, 바람직하게는 30℃ 내지 33℃이다.In addition, in the method for producing slug powder according to the present invention, the set drying temperature is 29°C to 35°C, preferably 30°C to 33°C.
또한, 본 발명에 따른 굼벵이 분말 제조방법에서, 설정된 건조시간은 1시간 내지 2시간이며 바람직하게는 2시간 30분이다.In addition, in the method for producing slug powder according to the present invention, the set drying time is 1 hour to 2 hours, preferably 2 hours 30 minutes.
본 발명에 따른 굼벵이 분말 제조방법에서 1차 건조단계는, 세척된 굼벵이를 진공챔버에 배치하고 감압하는 단계 및 진공챔버 내부가 설정된 압력까지 감압되면 진공챔버 내부에 마이크로파를 인가하는 단계를 포함한다.The primary drying step in the slug powder manufacturing method according to the present invention includes the steps of placing the washed slugs in a vacuum chamber and reducing the pressure, and applying microwaves to the inside of the vacuum chamber when the pressure inside the vacuum chamber is reduced to a set pressure.
또한, 초기 함수율은 77%가 바람직하다.In addition, the initial moisture content is preferably 77%.
일반적으로 진공 건조 방식은, 수분이 급속도로 증발하기 때문에, 건조 대상물의 조직이 파괴되거나 또는 변형될 가능성이 크다.In general, in the vacuum drying method, since moisture evaporates rapidly, the tissue of the object to be dried is highly likely to be destroyed or deformed.
본 발명에 따른 굼벵이 분말 제조방법에서, 1차 건조 단계는, 세척된 굼벵이를 진공챔버에 배치하고 감압하는 단계와, 진공챔버의 감압상태를 미리 정해진 감압시간동안 유지하는 감압 유지단계 및 감압시간 경과후 진공챔버 내부에 마이크로파를 인가하는 단계를 포함할 수 있다.In the method for producing slug powder according to the present invention, the primary drying step includes the steps of placing the washed slugs in a vacuum chamber and decompressing, maintaining the reduced pressure in the vacuum chamber for a predetermined decompression time, and the lapse of decompression time Then, it may include applying a microwave to the inside of the vacuum chamber.
완숙되어 세척된 굼벵이를 진공챔버에 넣어 감압하면, 굼벵이의 표피는 물론이고 물러진 굼벵이 조직이 부풀어 오르며 압력 감소에 의해 내부의 수분이 증발하기 시작한다. When the fully ripened and washed slugs are put in a vacuum chamber and reduced pressure, the skin of the slugs as well as the soft slug tissue swells up, and the moisture inside starts to evaporate due to the decrease in pressure.
감압시간동안 감압 상태를 유지하면, 굼벵이의 가열되지 않으면서도 조직이 이완된다. If the decompression state is maintained for the decompression time, the tissue of the slugs is relaxed without being heated.
감압 유지 시간 경화후 마이크로파를 인가하면, 굼벵이 조직 내부의 수분이 가열되어, 외부로 급속 방출된다.After curing under reduced pressure, if microwaves are applied, the moisture inside the slug tissue is heated and rapidly released to the outside.
이 과정에서 굼벵이의 조직이 붕괴되거나 또는 변형된다. 이러한 조직 변형은 이후 수행되는 2차 건조 단계의 건조 효율이 높아지는 효과를 갖는다.In this process, the slug's tissue is destroyed or deformed. This tissue modification has the effect of increasing the drying efficiency of the secondary drying step performed thereafter.
또한 1차 건조를 진공 건조함으로써, 굼벵이 조직 내부의 향기성분이 제거될수 있는 장점이 있다.In addition, by vacuum drying the primary drying, there is an advantage that the fragrance component inside the slug tissue can be removed.
1차 건조 단계에서 초기 함수율이 높으면, 2차 건조단계의 건조시간이 길어지는 문제점이 있다.If the initial moisture content in the primary drying step is high, there is a problem in that the drying time in the secondary drying step is long.
반면에 초기 함수율이 과도하게 낮으면, 굼벵이의 조직 파괴가 심화되어 1차 건조단계 이후의 작업성이 나빠지는 문제점이 있다. On the other hand, if the initial moisture content is excessively low, the tissue destruction of the slugs is deepened, and there is a problem in that workability after the first drying step is deteriorated.
초기 함수율은 75% 내지 80%, 바람직하게는 77%를 달성함으로써, 굼벵이가 반 건조 상태이며 그 형태를 유지함으로써, 2차 건조단계의 작업이 용이하게 수행될 수 있다.By achieving the initial moisture content of 75% to 80%, preferably 77%, the slugs are semi-dry and maintain their shape, so that the operation of the secondary drying step can be easily performed.
본 발명에 따른 굼벵이 분말 복용방법은, 상술한 굼벵이 분말 제조방법으로 제조된 굼벵이 분말을 복용자에게 경구 투여하는 방법을 단계를 포함한다.The method for taking slug powder according to the present invention includes a method of orally administering to a user the slug powder prepared by the above-described method for preparing slug powder.
이때, 투여는 복용자에게 하루에 100 내지 3,000mg/kg.B.W.의 굼벵이 분말의 총 일일 투여량을 제공한다.At this time, the administration provides the recipient with a total daily dose of 100 to 3,000 mg/kg.B.W. slug powder per day.
총 일일 투여량은 100 내지 300mg/kg.B.W.일 수 있다.The total daily dose may be between 100 and 300 mg/kg.B.W.
총 일일 투여량을 선택적으로 2회 또는 그 이상을 분할 투여할 수 있다.The total daily dose may optionally be administered in two or more divided doses.
실시예 - 금벵이 분말의 in vivo 항혈전 활성 효능검증.Example - Verification of the in vivo antithrombotic activity of ginseng powder.
실험 평가 항목Experimental evaluation items
식품의약품안전청의 건강기능식품 기능성 평가 가이드라인(2015) -‘혈행개선에 도움을 줄 수 있음’편-을 참조하여 실험하였다.The experiment was conducted with reference to the Food and Drug Administration's functional evaluation guidelines for health functional foods (2015) - 'Can help improve blood circulation'.
실험군experimental group
실험군은, 총 8군으로 구분하였다.The experimental group was divided into a total of 8 groups.
총 8군의 실험군은, 정상식이군(G1), 굼벵이(G2, 3,000mg/㎏ B.W.)군, CCl4 투여군(G3), CCl4+ pycno-genol(G4, 500mg/kg B.W.)군, CCl4+굼벵이(G5, 100mg/kg B.W.)군, CCl4+굼벵이(G6, 300mg/kg B.W.)군, CCl4+굼벵이(G7, 1,000mg/kg B.W.)군, CCl4+굼벵이 (G8, 3,000mg/kg B.W.)군이며, 아래의 표 3은 상술한 총 8군의 실험군의 구성 및 투여량을 비교하여 나타내었다.A total of 8 experimental groups were: normal diet group (G1), slugs (G2, 3,000 mg/kg B.W.) group, CCl4 administration group (G3), CCl4+ pycno-genol (G4, 500 mg/kg B.W.) group, CCl4+ slugs (G5, 100mg/kg B.W.) group, CCl4+ slug (G6, 300mg/kg B.W.) group, CCl4+slug (G7, 1,000mg/kg B.W.) group, CCl4+ slug (G8, 3,000mg/kg B.W.) group, Table 3 below is shown by comparing the composition and dosage of the experimental group of the above-mentioned 8 groups.
(mg/kg B.W.)daily dose
(mg/kg BW)
(mL/kg)dose amount
(mL/kg)
G3 실험군에서 CCl4는 Olive oil을 사용하여 25%로 희석한 후 4 ml/kg B.W으로 주 2회 복강 투여하였다.In the G3 experimental group, CCl 4 was diluted to 25% with olive oil and then administered intraperitoneally at 4 ml/kg BW twice a week.
실험동물laboratory animal
체중 250 g 내외의 6주령 SD-수컷 쥐를 각 실험군(G1~G8)마다 10마리씩 총 80마리를(㈜샘타코, BIO KOREA)에서 구입하여 실험에 사용하였다. 환경에 적응시키기 위해 일반 배합사료로 1주일간 예비사육한 후 정상식이군(G1)은 1314 IRR[Altromin Spezialfutter GmbH & Co. KG(Im Seelenkamp 20, D-3 2791 Lage Postfach 11 20, D-32770 Lage_Germany)] 기본식이로 공급하였다. Six-week-old SD-male rats weighing about 250 g were purchased from 10 rats in each experimental group (G1 to G8) (Samtaco Co., Ltd., BIO KOREA) and used in the experiment. In order to adapt to the environment, the normal diet group (G1) had 1314 IRR [Altromin Spezialfutter GmbH & Co. KG (
본 실험에서는 굼벵이 분말의 항혈전효능을 알아보기 위해 모든 동물에 대하여 굼벵이 분말 혹은 양성대조군인 pycnogenol을 매일 동일한 시간에 CCl4투여 전 5일간 5회 경구 투여하였다. In this experiment, to examine the antithrombotic effect of slug powder, pycnogenol as a slug powder or positive control was orally administered 5 times for 5 days before CCl 4 administration at the same time every day to all animals.
이후 정상식이군(G1)과 사염화탄소(CCl4, Carbontetrachloride)를 이용한 혈액응고계 이상 동물군인 CCl4군(G3)으로 구분하였다. After that, the normal diet group (G1) and carbon tetrachloride (CCl 4 , Carbontetrachloride) was classified into CCl 4 group (G3), which is an animal group with abnormal blood coagulation system.
사육장은 폴리카보네이트 사육 상자를 사용하였고, 온도 및 습도는 22±2℃, 55±5%로 조정하였고, 명암은 8:00am-8:00pm으로 12시간 마다 실내조명을 명/암으로 유지하였다.The breeding house used a polycarbonate breeding box, and the temperature and humidity were adjusted to 22±2℃, 55±5%, and the light and dark was maintained at 8:00am-8:00pm, and the indoor lighting was maintained at light/dark every 12 hours.
투여물질substance to be administered
굼벵이+Vit C, 굼벵이 혹은 pycnogenol을 100, 300, 1,000 및 3,000㎎/㎏ bw을 실험동물에게 4주간 섭취시켰으며 표 1과 같다.100, 300, 1,000, and 3,000 mg/kg bw of slugs + Vit C, slugs or pycnogenol were ingested to the experimental animals for 4 weeks, as shown in Table 1.
검사test
실험동물에 대한 검사는 체중증가량, 부검, 혈액검사 및 조직병리학적 검사를 수행하였다.For laboratory animals, weight gain, autopsy, blood tests, and histopathological tests were performed.
체중증가량 weight gain
실험 동물 도입 시, 상술한 총 8군 분리 시, 투여기간 중 주 1회 및 부검당일에 측정하였다.Measurements were made once a week during the administration period and on the day of autopsy when the experimental animals were introduced, when the above-mentioned 8 groups were separated.
부검autopsy
실험전일 12시간 전부터 식이를 제거한 후 실험 당일 실험동물의 체중을 측정하였다. 복부 지방량은 에테르를 사용하여 마취한 후 복부를 절개하여 부고환주위의 지방과 신장주변의 지방을 모두 적출하여 무게를 측정하였다.After removing the diet from 12 hours before the day before the experiment, the body weight of the animals was measured on the day of the experiment. Abdominal fat mass was measured by anesthetizing with ether and then excising the abdominal incision to extract both the fat around the epididymis and the fat around the kidney.
혈액검사blood test
채혈된 혈액 중 일부는 실온에서 30 분 동안 방치한 후 3,000 rpm에서 20 분간 원심분리 하여 혈청을 분리하며 분석에 사용되기 전까지 -70。C에 보관하였다. Sod citrate tube에 담은 혈액은 3,000 rpm에서 20 분간 원심분리 하여 혈장을 분석에 사용되기 전까지 -70。C에 보관하였다. Triglyceride (TG), Total cholesterol (T-CHO), High density lipiprotein cholesterol (HDL-c), Low density lipiprotein cholesterol (LDL-c), Aspartate transaminase (AST), Alanine transaminase (ALT), Alkaline phosphatase (ALP), Blood urea nitrogen (BUN), Creatinine (CRE), Total protein (TP), Albumin (ALB) 분석에는 혈청을 사용하였으며 자동생화학분석장치 (Hitachi 3100, Hitachi Ltd, Japan)를 사용하였다. Prothrombin time (PT), Activated partial thromboplastin time (aPTT). Fibrinogen (Fbg) 분석에는 자동응고계분석장치 (CA660, Sysmex Co. Ltd)를 사용하였다.Some of the blood collected was left at room temperature for 30 minutes and then centrifuged at 3,000 rpm for 20 minutes to separate serum and stored at -70°C until used for analysis. Blood in sodium citrate tube was centrifuged at 3,000 rpm for 20 minutes and plasma was stored at -70°C until used for analysis. Triglyceride (TG), Total cholesterol (T-CHO), High density lipiprotein cholesterol (HDL-c), Low density lipiprotein cholesterol (LDL-c), Aspartate transaminase (AST), Alanine transaminase (ALT), Alkaline phosphatase (ALP) , Blood urea nitrogen (BUN), Creatinine (CRE), Total protein (TP), and Albumin (ALB) were analyzed using serum, and an automatic biochemical analyzer (Hitachi 3100, Hitachi Ltd, Japan) was used. Prothrombin time (PT), Activated partial thromboplastin time (aPTT). An automatic coagulation analyzer (CA660, Sysmex Co. Ltd) was used for fibrinogen (Fbg) analysis.
조직병리학적 검사histopathological examination
조직병리학적 검사 : 조직병리학적 검사는 formalin에 고정된 간 조직을 사용하여 실시하였다. 고정이 완료된 조직을 약 4 mm 두께로 삭정한 후 일반적 조직처리과정과 포매 과정을 거쳐 파라핀 블록으로 제작하였다. 그 후 회전식 microtome을 사용하여 4 ㎛두께로 박절한 후 Hematoxylin and eosin stain (HE stain)과 Masson trichrome stain을 실시하였다. 염색된 슬라이드를 광학현미경으로 관찰하면서 섬유화 (chirosis) 면적에 따라 0 ~ 4점으로 분류하였다.Histopathological examination: Histopathological examination was performed using liver tissue fixed in formalin. After the fixed tissue was cut to a thickness of about 4 mm, it was made into a paraffin block through general tissue processing and embedding process. After that, sections were cut to a thickness of 4 μm using a rotary microtome, and then Hematoxylin and eosin stain (HE stain) and Masson trichrome stain were performed. While observing the stained slides with an optical microscope, they were graded from 0 to 4 points according to the area of chirosis.
분석analysis
모든 실험결과는 실험동물 8마리의 평균치와 표준오차로 표기하였으며 각 군간 차이의 유의성을 알기 위한 통계학적 방법은 SPSS 18.0 (Statistical Pack -age for Social Sciences, SPSS Inc., Chicagom IL, USA) 소프트웨어 프로그램을 이용하여 Duncan's multiple range test를 행하였다.All experimental results were expressed as the average value and standard error of 8 animals. The statistical method to know the significance of the difference between each group is SPSS 18.0 (Statistical Pack -age for Social Sciences, SPSS Inc., Chicagom IL, USA) software program. Duncan's multiple range test was performed using
결과result
체중, 간 및 신장조직 무게.body weight, liver and kidney tissue weight.
아래의 표 4는 총 8군의 실험군의 체중 및 장기 중량 무게이다. 각 값은 평균 ±표준편차 이며, n=8이다.Table 4 below shows the body weight and organ weight of the experimental group of a total of 8 groups. Each value is the mean ± standard deviation, n=8.
표 4에 따르면, 체중, 간 및 신장조직의 무게를 측정한 결과, 절대 및 상대 장기 무게에서 유의적인 변화는 확인되지 않았다.According to Table 4, as a result of measuring body weight, liver and kidney tissue weight, no significant change was found in absolute and relative organ weight.
혈액학적 변화에 미치는 효과 Effect on Hematological Changes
다음의 표 5는 총 8군의 실험군의 생화학적 지표이다.Table 5 below is the biochemical index of the experimental group of a total of 8 groups.
표 5에 따라 각 실험군의 혈액학적 변화를 비교하면 다음과 같다.According to Table 5, hematological changes of each experimental group are compared as follows.
- 실험군 전체(G1~G8)에 대해서 Total protein(TP)와 알부민(Alb)은 샘플처리에 따른 통계적 유의성은 없었었다. TP의 경우 간질환시에 생산이 부족하여 감소를 하게 되며, 또한 간질환 시 면역 글로블린 증에서 증가하는데, 본 실험에서는 알부민의 수치가 거의 변화가 없는 것으로 확인되어 일부 감소는 간질환 시 기능부전의 영향일 가능성이 크다고 판단된다.- For the entire experimental group (G1 to G8), there was no statistical significance in total protein (TP) and albumin (Alb) according to sample treatment. In the case of TP, the production of TP decreases due to insufficient production in liver disease, and it increases in immunoglobulinosis during liver disease. is considered to be highly probable.
- 혈청 내 간 손상의 지표인 AST는 무처리군인 G1과 G2에 비하여 G3~G8 모두 증가하는 경향을 보였으나, 사염화탄소 단독투여군인 G3과 비교하였을 때는 시료처리군(G4~G8) 모두 감소하는 경향을 보였는데 특히, 굼벵이 분말 100 ㎎/㎏투여군(G5)이 39.8%정도로 유의하게 감소하였고, 이후 증가하는 경향을 나타내었다.- AST, which is an indicator of liver damage in serum, showed a tendency to increase in both G3~G8 compared to G1 and G2 in the untreated group. In particular, the
- 또한 ALT의 경우에는 무처리군인 G1과 G2에 비하여 G3~G8 모두 증가하는 경향을 보였으나, 사염화탄소 단독투여군인 G3과 비교하였을 때는 시료처리군(G4~G8) 모두 감소하는 경향을 보였는데 특히 굼벵이 분말 300 ㎎/㎏ 투여군(G6)이 33.5%정도로 유의하게 감소하였고, 이후 증가하는 경향을 나타내었다.- In the case of ALT, both G3~G8 showed a tendency to increase compared to the untreated group G1 and G2, but compared with G3, the carbon tetrachloride alone group, all of the sample treated groups (G4~G8) showed a tendency to decrease. The slug powder 300 mg/kg administration group (G6) significantly decreased by about 33.5%, and showed a tendency to increase thereafter.
- 한편, 사염화탄소(CCl4)에 의한 간 손상을 확인하고자 하는 지표로 사용하는 효소는 AST, ALT, alanine transamidase, lactate dehydrogenase, ornitine carbonyl transferase 등으로 그 수치가 증가하는 것으로 판단을 하는데, 특히 AST, ALT의 활성은 간 손상의 정도를 측 하는 지표로서 임상실험에서 널리 이용되고 있다.- On the other hand, the enzyme used as an indicator to check liver damage caused by carbon tetrachloride (CCl 4 ) is AST, ALT, alanine transamidase, lactate dehydrogenase, ornitine carbonyl transferase, etc. ALT activity is widely used in clinical trials as an indicator to measure the degree of liver damage.
- AST와 ALT의 증가는 간세포성의 질환에서 발생하는 현상이며, ALP는 종양, 간염, 간경화등에 의한 간내성 폐쇄 등에 의해 증가가 되는데, 본 실험에서는 사염화탄소의 투여에 의해서 AST, ALT ALP가 유의하게 증가되었지만, 굼벵이 분말 투여군의 경우 저농도 (100 mg~300 mg)인 G5 및 G6에서는 사염화탄소의 단독투여군(G3)에 비해 유의적으로 감소하여 이후 고농도 군(G7~G8)에서는 다시 증가하는 경향을 나타내었다.- The increase in AST and ALT is a phenomenon that occurs in hepatocellular diseases, and ALP is increased due to hepatic refractory obstruction due to tumor, hepatitis, cirrhosis, etc. In this experiment, AST and ALT ALP were significantly increased by administration of carbon tetrachloride. However, in the case of the slug powder administration group, the low concentration (100 mg~300 mg) G5 and G6 showed a significant decrease compared to the carbon tetrachloride single administration group (G3), and thereafter, the high concentration group (G7 ~ G8) showed a tendency to increase again. .
따라서 G5, G6군에서 굼벵이 혼합분말이 간세포의 손상을 복구하는데 큰 역할을 하는 것으로 판단된다.Therefore, it is judged that the mixed powder of slugs in the G5 and G6 groups plays a major role in repairing the damage to the hepatocytes.
혈액응고저해에 미치는 영향Effect on blood clotting inhibition
도 1은 총 8군의 실험군의 혈액응고 저해활성이다.1 is a blood coagulation inhibitory activity of a total of 8 groups.
- 혈액개선 평가를 위해 측정한 혈액응고지표인 PT와 aPTT는 혈액 응고시스템 줌 extrinsic pathway와 intrinsic pathway를 각각 반영하는 지표로 항혈전 효과 추정할 수 있다. - PT and aPTT, which are blood coagulation indicators measured for blood improvement evaluation, are indicators that reflect the extrinsic pathway and the intrinsic pathway of the blood coagulation system, respectively, and the antithrombotic effect can be estimated.
외인성 응고계의 선별검사인 PT는 Ca2+이 포함된 tissue- thromboplastin을 혈장에 넣어 응고 시간을 측정함으로써 외인성 응고계에 작용하는 혈장 응고인자인 II, VII, X과 섬유소원 등의 농도 및 기능을 평가하기 위해 이용된다. PT, a screening test for the exogenous coagulation system, puts tissue-thromboplastin containing Ca 2+ into plasma and measures the coagulation time to measure the concentration and function of plasma coagulation factors II, VII, X and fibrinogen acting on the exogenous coagulation system. used to evaluate
한편, aPTT는 응고기전의 전체적인 선별검사이며 특히 intrinsic pathway의 전반적인 기능(응고인자 II, VII, IX, X, XI, XII)을 평가하는 예민한 검사이다.On the other hand, aPTT is an overall screening test for the coagulation mechanism, and is a sensitive test that evaluates the overall function of the intrinsic pathway (coagulation factors II, VII, IX, X, XI, XII).
- 도 1에서 보는 바와 같이 혈액응고 관련지표인 PT와 aPTT는 G5 (100 mg), G6 (300 mg)에서 양성대조군인 pycnogenol (G4)과 비교하여 통계학적으로 유의한 감소가 확인되었으나, 300 mg이상 투여군(G7~G8)에서는 다시 연장되는 경향을 보였다. - As shown in FIG. 1, PT and aPTT, which are blood coagulation-related indicators, were statistically significantly decreased in G5 (100 mg) and G6 (300 mg) compared to the positive control pycnogenol (G4), but 300 mg In the abnormally administered group (G7~G8), there was a tendency to extend again.
그러나 대조군에 비하여 굼벵이 분말 첨가군의 PT가 연장되는 경향을 보였으며, aPTT는 대조군에 비해 고지방 대조군에서 감소하였다가 굼벵이 분말 첨가에 따라 증가되는 경향을 보였다. However, compared to the control group, the PT of the slug powder addition group showed a tendency to prolong, and the aPTT decreased in the high fat control group compared to the control group, but showed a tendency to increase according to the slug powder addition group.
PT, aPPT의 연장현상은 혈액응고 인자의 결핍에 기인하며, 이는 간기능의 활성화 여부와도 관계한다.The prolongation of PT and aPPT is due to the deficiency of blood coagulation factors, which is also related to the activation of liver function.
G5, G6에서 PT, aPPT의 유의한 감소는 간손상이 최소화도니 것으로 판단할 수 있다. A significant decrease in PT and aPPT in G5 and G6 can be judged to indicate that liver damage is minimal.
또한 혈액응고 인자인 fibrinogen 역시 굼벵이첨가량에 따라 유의적으로 감소하였는데 이는 굼벵이 분말첨가가 혈액 응고를 지연시켜 혈행장애 개선에 기여할 가능성이 있다고 판단된다. In addition, fibrinogen, a blood coagulation factor, also decreased significantly according to the amount of slugs added, which is considered to be likely to contribute to the improvement of blood circulation disorders by delaying blood coagulation.
간조직의 변화에 미치는 영향Effect on changes in liver tissue
도 2는 총 8군의 실험군의 간조직에 대한 조직학적 검사이다.2 is a histological examination of liver tissues of a total of 8 experimental groups.
도 2에서 확인되듯이 간의 상태를 확인하기 위하여 MT stain과 HE stain을 실시한 결과, 정상군(G1)과 정상동물에 굼벵이 3,000 mg을 투여한 G2군에서는 간소엽, sinusoid 구조의 변성이나 중심 정맥성주위성 변화, 담관 및 문맥주위의 특이적인 변화는 관찰되지 않은 반면 사염화탄소 단독투여군(G3)에서 상당한 괴사, 지방침착이 관찰되었으며 일부 동물에서는 출혈이 확인되었다.As shown in FIG. 2 , as a result of performing MT stain and HE stain to confirm the condition of the liver, in the normal group (G1) and in the G2 group administered with 3,000 mg of slugs in normal animals, degeneration of liver lobules and sinusoid structures or central venous strain Satellite changes, specific changes in the bile duct and portal vein were not observed, whereas significant necrosis and fat deposition were observed in the carbon tetrachloride alone group (G3), and bleeding was confirmed in some animals.
또한, 굼벵이 투여군 중 3,000 mg (G8)을 제외한 모든 군에서 통계학적으로 유의적인 감소가 확인되었으며 양성대조물질로 사용한 pycnogenol 투여군(G4)에서도 유의적으로 감소하여 굼벵이 분말투여(G5~G8)로 사염화탄소에 의해 유도되는 간손상을 억제할 수 있음을 확인하였다.In addition, a statistically significant decrease was confirmed in all groups except for 3,000 mg (G8) of the slugs administered group, and also significantly decreased in the pycnogenol administration group (G4), which was used as a positive control. It was confirmed that it can inhibit liver damage induced by
실험 결과 Experiment result
본 발명에 따른 굼벵이 분말 복용방법은, 굼벵이 분말의 간기능 향상 및 간손상을 복구하는데 효과적인 것으로 확인되었다. It was confirmed that the method for taking slug powder according to the present invention is effective for improving liver function and repairing liver damage of slug powder.
Claims (7)
상기 1차 건조단계에서 제공되는 상기 굼벵이를 미리 설정된 건조온도 및 건조시간으로 건조하는 2차 건조단계; 및
상기 2차 건조단계에서 제공되는 상기 굼벵이를 분쇄하여 굼벵이 분말을 제조하는 분쇄단계;를 포함하고,
상기 설정된 건조온도는 29℃ 내지 35℃이며,
상기 설정된 건조시간은 1시간 내지 2시간이고,
상기 1차 건조단계는,
세척된 상기 굼벵이를 진공챔버에 배치하고 감압하는 단계;
상기 진공챔버의 감압상태를 미리 정해진 감압 시간동안 유지하는 감압 유지단계;
상기 감압시간 경과후 상기 진공챔버 내부에 마이크로파를 인가하는 단계;를 포함하며,
상기 초기 함수율은 77%인 굼벵이 분말 제조 방법.A primary drying step of washing the mature slugs and lowering the moisture content of the slugs washed by a low-temperature vacuum drying method using a microwave to a set initial moisture content;
a secondary drying step of drying the slugs provided in the primary drying step at a preset drying temperature and drying time; and
Grinding step of pulverizing the slugs provided in the secondary drying step to produce slug powder;
The set drying temperature is 29 ℃ to 35 ℃,
The set drying time is 1 hour to 2 hours,
The first drying step is
placing the washed slugs in a vacuum chamber and reducing the pressure;
a decompression maintaining step of maintaining the decompression state of the vacuum chamber for a predetermined decompression time;
and applying microwaves to the inside of the vacuum chamber after the decompression time has elapsed;
The initial moisture content is 77% slug powder manufacturing method.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190130690A KR102413828B1 (en) | 2019-10-21 | 2019-10-21 | Method of Manufacturing and Taking Grub Powder |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190130690A KR102413828B1 (en) | 2019-10-21 | 2019-10-21 | Method of Manufacturing and Taking Grub Powder |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210047077A KR20210047077A (en) | 2021-04-29 |
KR102413828B1 true KR102413828B1 (en) | 2022-06-28 |
Family
ID=75728466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190130690A KR102413828B1 (en) | 2019-10-21 | 2019-10-21 | Method of Manufacturing and Taking Grub Powder |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102413828B1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107319456A (en) * | 2017-07-31 | 2017-11-07 | 福建农林大学 | A kind of microwave vacuum drying method of queen bee nit dry powder |
KR101852840B1 (en) * | 2018-01-02 | 2018-04-27 | 주식회사 한미양행 | Hepatoprotective composition comprising enzyme treated larva |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100353753B1 (en) | 1999-11-26 | 2002-09-26 | 백상인 | Manufacture method of maggot powder |
KR101909581B1 (en) * | 2017-02-20 | 2018-10-18 | (주)제주바이오세상 | A making method of food and health-help food used white grub |
-
2019
- 2019-10-21 KR KR1020190130690A patent/KR102413828B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107319456A (en) * | 2017-07-31 | 2017-11-07 | 福建农林大学 | A kind of microwave vacuum drying method of queen bee nit dry powder |
KR101852840B1 (en) * | 2018-01-02 | 2018-04-27 | 주식회사 한미양행 | Hepatoprotective composition comprising enzyme treated larva |
Also Published As
Publication number | Publication date |
---|---|
KR20210047077A (en) | 2021-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lee et al. | Hepatoprotective effects of blue honeysuckle on CCl4‐induced acute liver damaged mice | |
Niwa et al. | Ipomoea batatas and Agarics blazei ameliorate diabetic disorders with therapeutic antioxidant potential in streptozotocin-induced diabetic rats | |
Gennaro et al. | Flavonoid and carbohydrate contents in Tropea red onions: effects of homelike peeling and storage | |
Sheng et al. | Anti‐obesity and hypolipidemic effect of water extract from Pleurotus citrinopileatus in C57 BL/6J mice | |
Kaviarasan et al. | Fenugreek seed (Trigonella foenum graecum) polyphenols inhibit ethanol-induced collagen and lipid accumulation in rat liver | |
Yuan et al. | Hypoglycemic and anti-inflammatory effects of seabuckthorn seed protein in diabetic ICR mice | |
Ajiboye et al. | Antihyperglycemic and antidyslipidemic activity of Musa paradisiaca‐based diet in alloxan‐induced diabetic rats | |
Taniguchi et al. | Effect of Japanese radish (Raphanus sativus) sprout (Kaiware‐daikon) on carbohydrate and lipid metabolisms in normal and streptozotocin‐induced diabetic rats | |
Zhang et al. | Antithrombotic effect of fermented Ophiopogon japonicus in thrombosis-induced rat models | |
Nguekouo et al. | Effect of boiling and roasting on the antidiabetic activity of Abelmoschus esculentus (Okra) fruits and seeds in type 2 diabetic rats | |
Ogbuagu et al. | Hepatotoxic effect of Xylopia aethiopica fruit in Wistar rats | |
Guo et al. | Effect of hot air drying temperature on the quality and antioxidant activity of Boletus edulis Bull.: Fr. | |
Zhao et al. | Comparison of the effects of raw and cooked adzuki bean on glucose/lipid metabolism and liver function in diabetic mice | |
KR102413828B1 (en) | Method of Manufacturing and Taking Grub Powder | |
KR20190047865A (en) | Composition for blood circulation from Cudrania tricuspidata fruit | |
Zong et al. | Antidiabetic Effect of Chinese yam (Dioscorea opposita Thunb.) in High‐Fat Diet/Streptozotocin‐Induced Diabetic Rats | |
Nnamonu et al. | Effects of Hibiscus Sabdariffa calyces aqueous extract on serum cholesterol, body weight and liver biomarkers of Rattus Novergicus | |
Aboraya et al. | Reishi mushroom (Ganoderma lucidum) intervention improves lipids profile and paraoxonase/arylesterase activities in serum as well as enhances haemostatic effects in streptozotocin-induced diabetic rats | |
Naseem et al. | The effects of Ginkgo biloba leaf extract on metabolic disturbances associated to alloxan-induced diabetic rats. | |
KR102266729B1 (en) | Composition for improving liver injury and liver disease comprising flower of Rosa rugosa Thunberg and Cinnamomum cassia PRESL | |
Queiroz et al. | Antihyperglycemic effect of Passiflora glandulosa cav. fruit rinds flour in streptozotocin-induced diabetic mice | |
Fitri et al. | Effects of Gambir leaves extract (Uncaria gambir Roxb.) in preventing the aging process inducted D-galactose on pancreas mice | |
KR20160097902A (en) | Manufacturing method of garlic stem powder and tablet manufacturing method using thereof | |
Tasnin et al. | A study on the antidiabetic property of a mixed herbal food | |
KR20200098123A (en) | An unripe apple extract composition suitable for antidiabetic use, and its extraction method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |